Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: Eisai and Biogen’s Leqembi® (lecanemab) Approved to Treat Alzheimer’s Disease in Japan

Sep 25, 2023

Eisai and Biogen announced that Leqembi® (lecanemab) intravenous infusion was approved in Japan for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD). On 21 August 2023, the Japanese Ministry of Health, Labour and Welfare committee recommended approval of Leqembi®.

Japan is the second country to grant approval of Leqembi®, following the traditional US FDA approval on 6 July 2023.